Kairos Pharma to Present Initial Phase 1 Data for ENV105 Lung Cancer Treatment at World Conference

Kairos Pharma Ltd. (NYSE American: KAPA) announced it will present initial Phase 1 data for its experimental cancer treatment ENV105 at the World Lung Cancer Conference in Barcelona, Spain, from September 6-9, 2025. The clinical-stage biopharmaceutical company focuses on developing innovative cancer therapeutics that address drug resistance and immune suppression in oncology.

Principal Investigator Dr. Karen Reckamp will present findings from the open-label trial titled "Combination of Osimertinib and Carotuximab for Advanced, EGFR-Mutated Non-Small Cell Lung Cancer Patients." The presentation will highlight the combination therapy of ENV105 with osimertinib, with the primary objective being to evaluate safety and tolerability in patients with advanced, EGFR-mutated non-small cell lung cancer.

ENV105 represents a novel approach to cancer treatment by targeting CD105, a protein identified as a key driver of resistance to various cancer treatments. According to company information available at https://ibn.fm/KAPA, elevation of CD105 in response to standard therapy results in resistance and disease relapse. The antibody aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.

The upcoming presentation at the World Lung Cancer Conference holds significant importance for the oncology community and patients battling non-small cell lung cancer. Lung cancer remains one of the leading causes of cancer-related deaths worldwide, and treatments that address drug resistance could substantially improve patient outcomes. The Phase 1 data will provide crucial insights into the safety profile and potential efficacy of this combination approach.

Beyond the lung cancer trial, ENV105 is also in a Phase 2 clinical trial for castrate-resistant prostate cancer, demonstrating the company's broader approach to addressing unmet medical needs across multiple cancer types. The dual development pathway suggests confidence in the mechanism of action targeting CD105-mediated resistance.

The World Lung Cancer Conference presentation represents an important milestone for Kairos Pharma and the oncology field. Positive initial data could pave the way for expanded clinical development and potentially offer new treatment options for patients who have developed resistance to existing therapies. The conference provides a platform for peer review and scientific discussion that could influence future research directions in combating treatment resistance in lung cancer.